The Platform Technology of Peptide-based Cancer Therapy
발표자
()
초록
내용
Production of a tumor-specific T cell is essential for cancer immunotherapy. Because of the low cost and easy CMC, the peptide vaccine was proposed as an effective immunotherapy tool in fighting against cancers. Diverse formats of peptide vaccines have been designed in the presence of specific peptides with epitope and adjuvant and tested in clinical trials. However, major clinical trials using the peptide vaccines failed for several reasons, but limited: the low stability of peptides, inappropriate adjuvant, the absence of codelivery of the peptide and adjuvant, and immune suppression by the tumor microenvironment.
We tried to develop an effective platform technology for the peptide-based cancer immunotherapy. A novel and defined TLR3 agonist, called Nexavant (NVT) was developed. NVT assists to induce a stronger anti-cancer efficacy with several advantages of homogeneity, stability, and quantitative in vivo kinetics. Nexavant was used for the platform development for cancer immunotherapy. Several strategies were adopted to increase efficacy for the T-cell induction by diverse peptide presentation method and adjuvant formulation. The final format showed dramatic increase of anti-cancer effect that is corresponding to CD8 T-cell response. The same therapeutic effects were consistent even in a late tumor model with a potent T-cell memory regardless of whether the epitope is self or foreign. The diverse application of the platform will be exemplified in several in vivo models.